NDRA

ENDRA Life Sciences Inc. [NDRA] Stock Forecast

Q: What is ENDRA Life Sciences Inc. stock symbol ?

ENDRA Life Sciences Inc. is a US stock, located in Ann arbor of Mi and trading under the symbol NDRA

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

NDRA Stock Summary

EPS has been increasing for the past 3 years (Yearly statements)

EPS has been increasing for the past 3 quarters (Quarter statements)

The Moving Average Convergence Divergence (MACD) for NDRA recently turned positive (within last 10 days).

An RSI reading of 70 or higher indicates an overbought or overvalued condition.

In the last year, shareholders have seen their holdings diluted. Dilution over past year is 51.72%

Currently unprofitable, and not expected to turn profitable in the coming year

Does not have any significance market cap ($12.68M)

NDRA has less than 1 year of cash runway

Top 10 Correlated ETFs

NDRA

Top 10 Correlated Stocks

NDRA

In the News

10:14 10 Dec 2023 NDRA

ENDRA Life Sciences Inc. (NDRA) Q3 2023 Earnings Call Transcript

ENDRA Life Sciences Inc. (NASDAQ:NDRA ) Q3 2023 Results Conference Call November 14, 2023 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations Francois Michelon - Chairman and Chief Executive Officer Michael Thornton - Chief Technology Officer Irina Pestrikova - Senior Director, Finance Conference Call Participants Edward Woo - Ascendiant Capital Operator Good day, and welcome to the ENDRA Life Sciences Third Quarter 2023 Financial Results Conference Call. All participants will be in a listen-only mode.

04:05 10 Dec 2023 NDRA

ENDRA Life Sciences to Report Third Quarter 2023 Financial Results on November 14, 2023

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three and nine months ended September 30, 2023 on Tuesday, November 14, 2023 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate d.

09:44 10 Dec 2023 NDRA

ENDRA Life Sciences Inc. (NDRA) Q2 2023 Earnings Call Transcript

ENDRA Life Sciences Inc. (NASDAQ:NDRA ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations Francois Michelon - Chairman and Chief Executive Officer Michael Thornton - Chief Technology Officer Irina Pestrikova - Senior Director, Finance Conference Call Participants Edward Woo - Ascendiant Capital Operator Good day, and welcome to the ENDRA Life Sciences Second Quarter 2023 Financial Results Conference Call. All participants will be in listen-only mode.

09:48 10 Dec 2023 NDRA

ENDRA Life Sciences Inc. (NDRA) Q1 2023 Earnings Call Transcript

ENDRA Life Sciences Inc. (NASDAQ:NDRA ) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations Francois Michelon - Chairman & Chief Executive Officer Michael Thornton - Chief Technology Officer Irina Pestrikova - Senior Director of Finance Conference Call Participants Edward Woo - Ascendiant Capital Operator Good day, and welcome to the ENDRA Life Sciences Inc. First Quarter 2023 Financial Results Conference Call. All participants will be in listen-only mode.

09:09 10 Dec 2023 NDRA

Why Is ENDRA Life Sciences (NDRA) Stock Down 16% Today?

ENDRA Life Sciences (NASDAQ: NDRA ) stock is sliding lower on Friday after revealing details of its public offering. ENDRA Life Sciences is offering up 862,500 shares of NDRA stock alongside 431,250 warrants to purchase more shares.

07:31 10 Dec 2023 NDRA

ENDRA Life Sciences Inc. (NDRA) Q4 2022 Earnings Call Transcript

ENDRA Life Sciences Inc. (NASDAQ:NDRA ) Q4 2022 Earnings Conference Call March 14, 2023 4:30 PM ET Company Participants Yvonne Briggs – LHA Investor Relations Francois Michelon – Chairman and Chief Executive Officer Michael Thornton – Chief Technology Officer Irina Pestrikova – Senior Director-Finance Conference Call Participants Vernon Bernardino – H.C. Wainwright & Company Edward Woo – Ascendiant Capital Operator Good afternoon, and welcome to the ENDRA Life Sciences Incorporated Fourth Quarter 2022 Financial Results Conference Call.

04:05 10 Dec 2023 NDRA

ENDRA Life Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 14, 2023

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three months and year ended December 31, 2022 on Tuesday, March 14, 2023 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m.

06:31 10 Dec 2023 NDRA

ENDRA Life Sciences Inc. (NDRA) Q3 2022 Earnings Call Transcript

ENDRA Life Sciences Inc. (NASDAQ:NDRA ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Yvonne Briggs - Investor Relations Francois Michelon - Chairman & Chief Executive Officer Michael Thornton - Chief Technology Officer Renaud Maloberti - Chief Commercial Officer Irina Pestrikova - Senior Director of Finance Conference Call Participants Edward Woo - Ascendiant Capital Operator Good day, and welcome to the ENDRA Life Sciences Third Quarter 2022 Financial Results Conference Call. All participants will be in a listen-only mode.

07:56 10 Dec 2023 NDRA

ENDRA Life Sciences Inc. (NDRA) CEO Francois Michelon on Q2 2022 Results - Earnings Call Transcript

ENDRA Life Sciences Inc. (NASDAQ:NDRA ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Yvonne Briggs - IR Francois Michelon - Chairman and CEO Mike Thornton - Chief Technology Officer Renaud Maloberti - CCO Irina Pestrikova - Senior Director, Finance Conference Call Participants Edward Woo - Ascendiant Capital Vernon Bernardino - H.C. Wainwright Operator Good day everyone, and welcome to the ENDRA Life Sciences' Second Quarter 2022 Financial Results Conference Call.

07:09 10 Dec 2023 NDRA

Which Penny Stocks Are Investors Buying Right Now? 3 to Watch

Why investors are buying these penny stocks right now The post Which Penny Stocks Are Investors Buying Right Now? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

NDRA Financial details

Company Rating

Neutral

Market Cap

12.68M

Income

-11.87M

Revenue

Book val./share

0.68

Cash/share

0.43

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

14 Nov 2023

P/E

-0.97

Forward P/E

-0.99

PEG

-0

P/S

P/B

2.22

P/C

3.49

P/FCF

-1.2

Quick Ratio

1.54

Current Ratio

2.95

Debt / Equity

0.08

LT Debt / Equity

0.05

EPS (TTM)

-1.09M

EPS next Y

-1.52

EPS next Q

-0.42

EPS this Y

-16.45%

EPS next Y

-100%

EPS next 5Y

-100%

EPS last 5Y

-36.28%

Revenue last 5Y

-100%

Revenue Q/Q

EPS Q/Q

-6.98%

SMA20

26.04%

SMA50

9.01%

SMA100

-12.32%

Inst Own

0.02%

Inst Trans

2.48%

ROA

-156%

ROE

-199%

ROC

-2.28%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

8.45M

Shs Float

8.28M

Target Price

52W Range

0.87-5.95

52W High

52W Low

RSI

82.21

Rel Volume

1.51

Avg Volume

109.09K

Volume

164.63K

Perf Week

55.93%

Perf Month

54.64%

Perf Quarter

8.7%

Perf Half Y

-5.06%

Beta

1.183

Volatility

0.16%, 0.16%

Prev Close

8.7%

Price

1.5

Change

7.14%

NDRA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.03	0	0	0	0
Net income per share	-43.49	-41.48	-12.47	-5.47	-4.57
Operating cash flow per share	-34.2	-22.9	-11.22	-5.44	-4.42
Free cash flow per share	-34.64	-23.02	-11.28	-5.46	-4.49
Cash per share	28.73	16.46	7.53	4.62	1.69
Book value per share	27.74	12.7	7.47	5.27	2.49
Tangible book value per share	27.74	12.7	7.47	5.27	2.49
Share holders equity per share	27.74	12.7	7.47	5.27	2.49
Interest debt per share	0	8.17	0.96	0.33	0.2
Market cap	6.76M	12.6M	14.39M	28.32M	11.77M
Enterprise value	285.92K	7.13M	7.85M	19.54M	7.43M
P/E ratio	-0.69	-0.81	-1.2	-2.53	-0.89
Price to sales ratio	1.09K	0	0	0	0
POCF ratio	-0.88	-1.47	-1.34	-2.55	-0.92
PFCF ratio	-0.87	-1.46	-1.33	-2.54	-0.91
P/B Ratio	1.08	2.65	2.01	2.63	1.63
PTB ratio	1.08	2.65	2.01	2.63	1.63
EV to sales	46.31	0	0	0	0
Enterprise value over EBITDA	-0.03	-0.66	-0.69	-1.73	-0.57
EV to operating cash flow	-0.04	-0.83	-0.73	-1.76	-0.58
EV to free cash flow	-0.04	-0.83	-0.73	-1.75	-0.57
Earnings yield	-1.45	-1.23	-0.83	-0.4	-1.12
Free cash flow yield	-1.15	-0.69	-0.75	-0.39	-1.1
Debt to equity	0	0.15	0.1	0.06	0.08
Debt to assets	0	0.1	0.08	0.05	0.06
Net debt to EBITDA	0.77	0.5	0.58	0.78	0.34
Current ratio	7.13	3.15	8.32	7.83	5
Interest coverage	0	-4.6	-49.49	0	-611.04
Income quality	0.79	0.65	0.92	0.99	0.97
Dividend Yield	0	0.33	0.03	0	0
Payout ratio	0	-0.27	-0.03	-0.01	0
Sales general and administrative to revenue	607.8	0	0	0	0
Research and developement to revenue	764.9	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.01	0.01	0	0	0.02
Capex to revenue	-16.2	0	0	0	0
Capex to depreciation	-1.46	-0.38	-0.31	-0.2	-0.86
Stock based compensation to revenue	0	0	0	0	0
Graham number	164.76	108.85	45.79	25.47	16
ROIC	-1.33	-2.16	-1.43	-0.95	-1.59
Return on tangible assets	-1.36	-2.17	-1.37	-0.87	-1.42
Graham Net	25.02	10.41	6.48	3.92	1.43
Working capital	5.97M	4.46M	7.23M	10.55M	6.82M
Tangible asset value	6.25M	4.76M	7.17M	10.78M	7.2M
Net current asset value	5.97M	4.12M	6.62M	10M	6.46M
Invested capital	0	0.15	0.1	0.06	0.08
Average receivables	76.14K	131.09K	253.77K	195.4K	0
Average payables	705.87K	954.95K	840.67K	596.98K	702.51K
Average inventory	125.56K	86.44K	351.53K	937.1K	1.96M
Days sales outstanding	8.6K	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0.04	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-1.57	-3.27	-1.67	-1.04	-1.83
Capex per share	-0.44	-0.12	-0.05	-0.02	-0.07

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric	2022-09-30	2022-12-31	2023-03-31	2023-06-30	2023-09-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0	0
Net income per share	-1.1	-1.09M	-0.93	-0.43	-0.4
Operating cash flow per share	-1.03	-1.03M	-0.79	-0.38	-0.34
Free cash flow per share	-1.03	-1.04M	-0.8	-0.38	-0.34
Cash per share	2.54	1.63M	0.74	0.8	0.43
Book value per share	3.23	2.4M	1.42	1.16	0.68
Tangible book value per share	3.23	2.4M	1.42	1.16	0.68
Share holders equity per share	3.23	2.4M	1.42	1.16	0.68
Interest debt per share	0.19	174.28K	0.16	0.08	0.06
Market cap	19.33M	12.21	7.26M	8.39M	8.53M
Enterprise value	11.9M	-4.34M	5.41M	4.05M	5.63M
P/E ratio	-1.4	0	-0.62	-0.82	-0.69
Price to sales ratio	0	0	0	0	0
POCF ratio	-5.95	0	-2.89	-3.7	-3.28
PFCF ratio	-5.93	0	-2.86	-3.7	-3.28
P/B Ratio	1.89	0	1.61	1.21	1.64
PTB ratio	1.89	0	1.61	1.21	1.64
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-3.54	1.34	-1.89	-1.39	-1.84
EV to operating cash flow	-3.66	1.41	-2.16	-1.78	-2.17
EV to free cash flow	-3.65	1.39	-2.14	-1.78	-2.17
Earnings yield	-0.18	-267.47K	-0.41	-0.3	-0.36
Free cash flow yield	-0.17	-256.12K	-0.35	-0.27	-0.3
Debt to equity	0.06	0.08	0.11	0.07	0.08
Debt to assets	0.05	0.06	0.08	0.05	0.06
Net debt to EBITDA	2.21	1.34	0.64	1.49	0.95
Current ratio	6.78	5	3.01	3.98	2.95
Interest coverage	-148.5	139.31	-859.96	0	0
Income quality	0.94	0.94	0.85	0.89	0.84
Dividend Yield	0	221.21	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0.01	0.01	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	-0.25	-0.57	-0.38	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	8.93	7.67M	5.45	3.33	2.48
ROIC	-0.3	-0.4	-0.54	-0.38	-0.52
Return on tangible assets	-0.28	-0.35	-0.44	-0.28	-0.41
Graham Net	2.28	1.38M	0.49	0.65	0.3
Working capital	9.86M	6.82M	3.69M	6.05M	4.23M
Tangible asset value	10.2M	7.2M	4.5M	6.93M	5.2M
Net current asset value	9.43M	6.46M	3.36M	5.77M	3.99M
Invested capital	0.06	0.08	0.11	0.07	0.08
Average receivables	0	0	0	0	0
Average payables	710.88K	625.33K	568.99K	469.48K	417.04K
Average inventory	2.5M	2.64M	2.69M	2.75M	2.76M
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.34	-0.45	-0.65	-0.37	-0.6
Capex per share	0	-12.85K	-0.01	0	0

NDRA Frequently Asked Questions

What is ENDRA Life Sciences Inc. stock symbol ?

ENDRA Life Sciences Inc. is a US stock , located in Ann arbor of Mi and trading under the symbol NDRA

What is ENDRA Life Sciences Inc. stock quote today ?

ENDRA Life Sciences Inc. stock price is $1.5 today.

Is ENDRA Life Sciences Inc. stock public?

Yes, ENDRA Life Sciences Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 109.09K
Market Capitalization 12.68M
Employee 21
CEO Mr. Francois Michelon
Headquarters Ann Arbor,MI,US
IPO Date 2017-06-30
Website https://www.endrainc.com

ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.